Clinical Trial

Fasenra: An Asthma Study

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-12.
Trial Details
NCT Number NCT07654842
Lead Sponsor Endeavor Health
Collaborators: AstraZeneca
Conditions Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Enrollment 40 participants
Start Date 2026-07-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-07